Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 764198 in focal segmental glomerulosclerosis
NCT05213624Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2022
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of apecotrep in focal segmental glomerulosclerosis (FSGS), sponsored by Boehringer Ingelheim. Started May 2022; status: completed.
02
Drugs
apecotrep
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT05213624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05213624.